Ameriprise’s Beam Therapeutics BEAM Stock Holding History

Ameriprise’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Buy	+8,910	New	+$269K	﹤0.01%	3832
2025 Q4	–	Sell	-88,732	Closed	-$2.15M	–	4088
2025 Q3	$2.15M	Buy	+88,732	New	+$1.77M	﹤0.01%	2968
2024 Q3	–	Sell	-230,172	Closed	-$5.39M	–	3933
2024 Q2	$5.39M	Buy	230,172 +1,267	+0.6%	+$31.1K	﹤0.01%	2246
2024 Q1	$7.56M	Sell	228,905 -37,090	-14%	-$1.16M	﹤0.01%	2037
2023 Q4	$7.24M	Buy	265,995 +249,865	+1,549%	+$6.21M	﹤0.01%	2060
2023 Q3	$388K	Buy	16,130 +6,657	+70%	+$178K	﹤0.01%	3498
2023 Q2	$302K	Buy	+9,473	New	+$307K	﹤0.01%	3604
2023 Q1	–	Sell	-7,337	Closed	-$287K	–	3940
2022 Q4	$287K	Sell	7,337 -49,291	-87%	-$2.21M	﹤0.01%	3600
2022 Q3	$2.7M	Buy	+56,628	New	+$3.23M	﹤0.01%	2639
2022 Q2	–	Sell	-9,732	Closed	-$558K	–	3897
2022 Q1	$558K	Buy	9,732 +7,217	+287%	+$473K	﹤0.01%	3444
2021 Q4	$200K	Buy	+2,515	New	+$215K	﹤0.01%	3788

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Ameriprise's BEAM Position: Q2 2026 in Review

Ameriprise opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 8,910 shares worth $306K. The stake represents ﹤0.01% of the portfolio and ranks #3832 among its holdings. This is a return to the name: Ameriprise previously reported a position in BEAM as recently as Q3 2025.

Ameriprise first reported a position in BEAM in Q4 2021 and has held it in 11 quarters since. The position peaked at $7.56M in Q1 2024. 278 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Ameriprise held 8,910 shares of Beam Therapeutics worth $306K as of Q2 2026.
Beam Therapeutics was a new Ameriprise position in Q2 2026.
Beam Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3832 holding.
Ameriprise first reported a position in Beam Therapeutics in Q4 2021 and has held it in 11 quarters since.
Ameriprise's Beam Therapeutics position peaked at $7.56M in Q1 2024.
278 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.